A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Efizonerimod-alfa (Primary) ; Durvalumab
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors MedImmune
- 12 Mar 2019 Status changed from active, no longer recruiting to completed.
- 20 Jun 2016 Planned number of patients changed from 224 to 39.
- 20 Jun 2016 Status changed from recruiting to active, no longer recruiting.